Spinal Muscular Atrophy (SMA): Epidemiology Forecast to 2027 - ResearchAndMarkets.com

July 5, 2018

DUBLIN--(BUSINESS WIRE)--Jul 5, 2018--The “Spinal Muscular Atrophy (SMA) - Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total diagnosed prevalent cases of SMA and diagnosed prevalence SMA cases by types (SMA Type 1, Type 2, Type 3 & Type 4)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to research, total prevalent population of Spinal Muscular Atrophy in 7 major markets is found out to be 38,900 in 2017.

Report Scope

The report covers detailed overview of SMA explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns The report provides the insight about the historical and forecasted patient pool of SMA in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan The Report assesses the disease risk and burden and highlights the unmet needs of the disease The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population The report provides the segmentation of the disease epidemiology by types (Type 1, Type 2, Type 3 & Type 4)

Key Strengths

10 Year Forecast of SMA epidemiology 7MM Coverage Diagnosed Prevalent cases of SMA Prevalent Cases according to segmentation: SMA by types (Type 1, Type 2, Type 3 & Type 4) in 7MM

Key Assessments

Patient Segmentation Disease Risk & Burden Risk of disease by the segmentation Factors driving growth in a specific patient population

Key Topics Covered

1. Report Summary

2. Spinal Muscular Atrophy: Background & Overview

3. Epidemiology and Patient Population

4. Appendix

5. Report Methodology

6. Consulting Services

For more information about this report visit https://www.researchandmarkets.com/research/c9zgkl/spinal_muscular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180705005389/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/05/2018 11:38 AM/DISC: 07/05/2018 11:38 AM


Update hourly